发明名称 |
Use of hyaluronic acid or its derivatives in peritoneal dialysis and formulations thereof |
摘要 |
A method of detoxifying a patient by peritoneal dialysis which patient will benefit from peritoneal dialysis treatment by involving underperfused or pathological tissue the administration of an agent suitable for peritoneal dialysis treatment, comprising administering to the patient a therapeutically effective dosage amount of a pharmaceutical composition for peritoneal dialysis treatment, each dosage amount comprising a therapeutically effective amount of an agent suitable for use in peritoneal dialysis and a sufficient amount of a form of hyaluronic acid selected from hyaluronic acid and non-toxic salts and combinations thereof sufficient to alter the agent's performance in the human body wherein said amount of the form of hyaluronic acid is sufficient to provide a dosage between 10 mg and 3000 mg of the form of hyaluronic acid and wherein the molecular weight of the form of hyaluronic acid is less than 750,000 daltons but greater than 150,000 daltons.
|
申请公布号 |
US5985851(A) |
申请公布日期 |
1999.11.16 |
申请号 |
US19960744852 |
申请日期 |
1996.11.18 |
申请人 |
HYAL PHARMACEUTICAL CORPORATION |
发明人 |
FALK, RUDOLF EDGAR;ASCULAI, SAMUEL S. |
分类号 |
A61K31/34;A61K;A61K9/00;A61K31/12;A61K31/136;A61K31/19;A61K31/192;A61K31/196;A61K31/282;A61K31/375;A61K31/40;A61K31/405;A61K31/407;A61K31/44;A61K31/505;A61K31/5415;A61K31/56;A61K31/70;A61K31/7034;A61K31/706;A61K31/715;A61K31/728;A61K38/00;A61K38/21;A61K45/00;A61K45/06;A61K47/00;A61K47/36;A61K47/48;A61P5/24;A61P9/00;A61P11/08;A61P17/00;A61P29/00;A61P35/00;A61P37/00;C08B37/08;(IPC1-7):A61K31/715 |
主分类号 |
A61K31/34 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|